Apr 17 |
BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
|
Apr 16 |
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
|
Apr 11 |
BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…
|
Apr 11 |
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
|
Apr 10 |
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
|
Apr 9 |
BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy
|
Apr 9 |
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
|
Apr 9 |
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
|
Apr 8 |
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
|
Apr 1 |
BrainStorm Cell Therapeutics GAAP EPS of -$0.40 beats by $0.16
|